Iterum Therapeutics plc (ITRM) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Iterum Therapeutics plc

ITRM

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

38M

Biotechnology

Next Earning date - 12 May 2025

38M

Biotechnology

Next Earning date - 12 May 2025

1.09USD

0.04 ( 3.86%)

Market Open

Relative Strenght

Volume Buzz

-70%

Earning Acce

Dist 52w H.

64%

Overview Chart

Quote Panel

Updated April 17, 2025

1W -0.90 % 1M -20.29 % 3M -27.63 % 1Y -23.08 %

Key Metrics

Market Cap
37.71M
Shares Outstanding
34.58M
Share in Float
34.06M
Dividende
0

Earning Date
12 May 2025
Price Target
1.0905
Average Volume
409222
Beta
2.876

Range
0.808-3.02
Industry
Biotechnology
Website
https://www.iterumtx.com
Sector
Healthcare

Quote Panel

Updated April 17, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

-5.07x

P/B Ratio

-11.2

Debt/Equity

0.0%

Net Margin

$-1.3

EPS

How ITRM compares to sector?

P/E Ratio

Fundamentals

Relative Strength

ITRM

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

ITRM

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$9M

NaN%

2025-Revenue

$0.70

-250%

2025-EPS

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Hold

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

H.C. Wainwright

upgrade

Previous: Not converted

2024-02-07

Now: Buy

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q1.23

N/A

-0.78
vs -0.30

Q2.23

N/A

-0.95
vs -0.60

Q3.23

N/A

-0.30
vs -2.38

Q4.23

N/A

-0.94
vs -0.41

Q1.24

N/A

-0.46
vs -0.78

Q2.24

N/A

-0.30
vs -0.95

Q3.24

N/A

-0.30
vs -0.30

Q4.24

N/A

-0.12
vs -0.94

Q1.25

N/A

-0.15
vs -0.46

Q2.25

N/A

-0.15
vs -0.30

Sales Growth

YoY

Current

Estimates

Q1.23

NA vs NA

Q2.23

NA vs NA

Q3.23

NA vs NA

Q4.23

2.6M vs NA

Q1.24

NA vs NA

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

-100%

NA vs 2.6M

Q1.25

2.7M vs NA

Q2.25

2.8M vs NA

Return on Equity

QoQ

Q1.23

-52%

-0.52
vs -0.18

Q2.23

-172%

-1.72
vs -0.52

Q3.23

-113%

-1.13
vs -1.72

Q4.23

+193%

1.93
vs -1.13

Q1.24

+115%

1.15
vs 1.93

Q2.24

+46%

0.46
vs 1.15

Q3.24

+53%

0.53
vs 0.46

Q4.24

+161%

1.61
vs 0.53

Institutionnal Ownership

QoQ

Q1.23

2
vs 3

-33%

Q2.23

2
vs 2

Q3.23

2
vs 2

Q4.23

2
vs 2

Q1.24

2
vs 2

Q2.24

1
vs 2

-50%

Q3.24

3
vs 1

200%

Q4.24

4
vs 3

33%

Earnings Growth

Latest News

globenewswire.com

7 hours ago

Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

globenewswire.com

8 hours ago

Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

globenewswire.com

8 hours ago

Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025

globenewswire.com

8 hours ago

Iterum Therapeutics Regains Full Nasdaq Compliance

seekingalpha.com

10 hours ago

Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript

seekingalpha.com

13 hours ago

Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript

Company Description

1.09USD

N/A

0.00x

-5.07x

-11.2

0.0%

$-1.3

$9M

$0.70

Earnings Growth

Latest News

$9M

$0.70

Company Description

1.09USD

N/A

0.00x

-5.07x

-11.2

0.0%

$-1.3